Protective effect and mechanism of ligustrazine combined with astragaloside IV on angiogenesis of human umbilical vein endothelial cells / 中草药

ABSTRACT

Objective: To study the protective effect and mechanism of ligustrazine combined with astragaloside IV on hypoxia injury of human umbilical vein endothelial cells (HUVECs). Methods: The model of hypoxia injury was established, and the cells for pharmacodynamics study were divided into five groups control group, model group, ligustrazine group (80 μg/mL), astragaloside IV group (40 μg/mL), and compatibility of astragaloside IV and ligustrazine group. The effects of ligustrazine, astragaloside IV, and their compatibility on cell proliferation in each group after hypoxia injury were detected by MTT assay. Immunohistochemical method was used to observe the expression of proteins VEGF and Ang-II in HUVECs with hypoxia injury, and Western blotting was used to observe the expression of proteins VEGF and Ang-II. RT-PCR was used to observe the mRNA expression of VEGF and Ang-II. Results: Compared with those in the model group, cell viability of ligustrazine group, astragaloside IV group, and compatibility group significantly increased, and the best group was ligustrazine (80 μg/mL)+astragaloside IV (40 μg/mL) group. Ligustrazine (80 μg/mL)+astragaloside IV (40 μg/mL) group could up-regulate the protein expression levels of VEGF and Ang-II and the levels of VEGF and Ang-II mRNA. Conclusion: Ligustrazine combined with astragaloside IV may be targeted by increasing angiogenesis factor, and the expression of VEGF and Ang-II plays the role of promoting angiogenesis.